CryoCell International Inc (CCEL) - Total Assets
Based on the latest financial reports, CryoCell International Inc (CCEL) holds total assets worth $63.17 Million USD as of August 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CryoCell International Inc - Total Assets Trend (1996–2024)
This chart illustrates how CryoCell International Inc's total assets have evolved over time, based on quarterly financial data. Also see CryoCell International Inc (CCEL) total market value for the company's overall valuation and market capitalisation.
CryoCell International Inc - Asset Composition Analysis
Current Asset Composition (November 2024)
CryoCell International Inc's total assets of $63.17 Million consist of 19.4% current assets and 80.6% non-current assets. Review total liabilities of CryoCell International Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.9% |
| Accounts Receivable | $7.31 Million | 11.3% |
| Inventory | $657.70K | 1.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $921.25K | 1.4% |
| Goodwill | $1.94 Million | 3.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how CryoCell International Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CCEL share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CryoCell International Inc's current assets represent 19.4% of total assets in 2024, a decrease from 42.9% in 1996.
- Cash Position: Cash and equivalents constituted 0.9% of total assets in 2024, down from 26.2% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 2.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 11.3% of total assets.
CryoCell International Inc Competitors by Total Assets
Key competitors of CryoCell International Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ramsay Health Care Ltd
AU:RHC
|
Australia | AU$21.70 Billion |
|
Surgery Partners Inc
NASDAQ:SGRY
|
USA | $7.95 Billion |
|
Chularat Hospital Public Company Limited
BK:CHG
|
Thailand | ฿10.15 Billion |
|
Sarana Meditama Metropolitan
JK:SAME
|
Indonesia | Rp5.71 Trillion |
|
Principal Capital Public Company Limited
BK:PRINC
|
Thailand | ฿16.51 Billion |
|
Bait Bakfar Ltd
TA:BKFR
|
Israel | ILA2.25 Billion |
|
Regis Healthcare Ltd
AU:REG
|
Australia | AU$2.11 Billion |
|
Oceania Healthcare Ltd
AU:OCA
|
Australia | AU$3.01 Billion |
CryoCell International Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.63 | 0.61 | 1.13 |
| Quick Ratio | 0.60 | 0.57 | 1.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.78 Million | $-6.76 Million | $2.14 Million |
CryoCell International Inc - Advanced Valuation Insights
This section examines the relationship between CryoCell International Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.72 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | 5.6% |
| Total Assets | $64.68 Million |
| Market Capitalization | $27.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values CryoCell International Inc's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CryoCell International Inc's assets grew by 5.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CryoCell International Inc (1996–2024)
The table below shows the annual total assets of CryoCell International Inc from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-11-30 | $64.68 Million | +5.65% |
| 2023-11-30 | $61.22 Million | -5.65% |
| 2022-11-30 | $64.89 Million | +6.97% |
| 2021-11-30 | $60.66 Million | +31.30% |
| 2020-11-30 | $46.20 Million | +7.73% |
| 2019-11-30 | $42.89 Million | +1.17% |
| 2018-11-30 | $42.39 Million | +77.29% |
| 2017-11-30 | $23.91 Million | +22.37% |
| 2016-11-30 | $19.54 Million | +0.21% |
| 2015-11-30 | $19.50 Million | +90.98% |
| 2014-11-30 | $10.21 Million | -11.23% |
| 2013-11-30 | $11.50 Million | -6.73% |
| 2012-11-30 | $12.33 Million | -36.66% |
| 2011-11-30 | $19.47 Million | +7.18% |
| 2010-11-30 | $18.16 Million | +24.33% |
| 2009-11-30 | $14.61 Million | +33.13% |
| 2008-11-30 | $10.97 Million | -5.68% |
| 2007-11-30 | $11.63 Million | -20.54% |
| 2006-11-30 | $14.64 Million | +2.86% |
| 2005-11-30 | $14.23 Million | +22.27% |
| 2004-11-30 | $11.64 Million | +61.29% |
| 2003-11-30 | $7.22 Million | -47.94% |
| 2002-11-30 | $13.86 Million | -20.30% |
| 2001-11-30 | $17.39 Million | +111.16% |
| 2000-11-30 | $8.24 Million | +49.77% |
| 1999-11-30 | $5.50 Million | +34.15% |
| 1998-11-30 | $4.10 Million | +2.50% |
| 1997-11-30 | $4.00 Million | -4.76% |
| 1996-11-30 | $4.20 Million | -- |
About CryoCell International Inc
Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manu… Read more